Immune responses and antitumor effects after radiofrequency ablation therapy in tumor patients

Abstract

Abstract:Radiofrequency ablation therapy not only causes the necrosis of localized tumor cells, but also produces immunogenic tumor associated antigens and a large number of inflammatory cytokines and a variety of immunogenic mediums, which promotes the local infiltration and activation of immune cells and stimulates the immune system to produce certain antitumor effect. But the intensity of antitumor effect is feeble and is insufficient to inhibit the growth of tumor cells. Radiofrequency ablation therapy combined with special immunotherapies, such as immune stimulants, adoptive immunity cells therapy, dendritic cell vaccines, monoclonal antibodies and so on, can maximize the clinical benefit, which is a good pattern about tumor comprehensive treatment containing immunotherapy.

Key words:Neoplasms,Immune system,Cytokines,Lymphocytes,Radiofrequency ablation

CAI Kai, ZHANG Chuang, JIANG Tao. Immune responses and antitumor effects after radiofrequency ablation therapy in tumor patients[J]. Journal of International Oncology, 2013, 40(11): 826-829.

References

［1］中国抗癌协会肝癌专业委员会，中国抗癌协会临床肿瘤学协作专业委员会，中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识. 肿瘤, 2011, 31(5): 385-388. ［2］ Waitz R, Solomon SB. Can local radiofrequency ablation of tumors generate systemic immunity against metastatic disease? Radiology, 2009, 251(1): 1-2. ［3］ Haen SP, Pereira PL, Salih HR, et al. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol, 2011, 2011:160250. ［4］ Goldberg SN. Science to practice: can we expand focal interventional oncologic ablation treatments into an effective systemic therapy?. Radiology, 2013,267(2):321-323. ［5］ Gravante G, Ong SL, Metcalfe MS, et al. The effects of radiofrequency ablation on the hepatic parenchyma: histological bases for tumor recurrences. Surg Oncol, 2011,20(4):237-245. ［6］ Gravante G, Sconocchia G, Ong SL, et al. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int, 2009,29(1):18-24. ［7］ Fietta AM, Morosini M, Passadore I, et al. Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol, 2009, 70(7):477-486. ［8］ Haen SP, Gouttefangeas C, Schmidt D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones, 2011,16(5):495-504. ［9］ Zerbini A, Pilli M, Fagnoni F, et al. Increased immunostimulatory activity conferred to antigenpresenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother, 2008, 31(3):271-282. ［10］ Dromi SA, Walsh MP, Herby S, et al. Radiofrequency ablation induces antigenpresenting cell infiltration and amplification of weak tumorinduced immunity. Radiology, 2009,251(1):58-66. ［11］ Wissniowski TT, Hansler J, Neureiter D, et al. Activation of tumorspecific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res, 2003,63(19):6496-6500. ［12］ Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radiofrequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol, 2006,12(23): 3716-3721. ［13］ Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol, 2005, 43(5):817-822. ［14］ Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor specific T-cell responses. Cancer Res, 2006, 66(2):1139-1146. ［15］ Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol, 2012, 40(1):63-70. ［16］ Napoletano C, Taurino F, Biffoni M, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2):481-490. ［17］崇杨，江涛，张东华，等. 射频消融术对原发性肝癌患者甲胎蛋白和外周血CD4+CD25+Foxp3+Treg细胞的影响. 江苏大学学报（医学版）, 2013,23(2): 177-179. ［18］ Liu Q, Zhai B, Yang W, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther, 2009, 17(12):2049-2057. ［19］ Johnson EE, Yamane BH, Buhtoiarov IN, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res, 2009, 15(15):4875-4884. ［20］ SanchezOrtiz RF, Tannir N, Ahrar K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol, 2003, 170(1): 178-179. ［21］ Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther, 2010, 9(11):903-907. ［22］ Kroeze SG, Daenen LG, Nijkamp MW, et al. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model. J Urol, 2012, 188(2):607-614. ［23］ Fagnoni FF, Zerbini A, Pelosi G, et al. Combination of radiofrequency ablation and immunotherapy. Front Biosci, 2008, 13:369-381.

[1]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[2]	Xu Kai, Wen Gang, Li Rui, Tian Yuan.Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms[J]. Journal of International Oncology, 2022, 49(10): 627-629.
[3]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao.Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer[J]. Journal of International Oncology, 2021, 48(9): 523-526.
[4]	Yang Wenqian, Huang Junxing.Research progress of immunotherapy in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(7): 429-432.
[5]	Ou Huiyi, Wang Yue, Peng Chenghong.Correlation between PD-L1 and Tregs in tumor immunity and immunotherapy[J]. Journal of International Oncology, 2021, 48(6): 350-353.
[6]	Liu Saisai, Yuan Dongya.Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment[J]. Journal of International Oncology, 2021, 48(4): 212-215.
[7]	Wang Tingting, Liu Lianke.Predictive values of preoperative LMR and PLR in early postoperative recurrence of patients with esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2020, 47(8): 467-471.
[8]	Sun Ye, Sheng Lixia, Ouyang Guifang.MicroRNAs and diffuse large B cell lymphoma[J]. Journal of International Oncology, 2019, 46(9): 566-569.
[9]	Zhang Yun, Ji Xiluan, Luo Zhaoxia, Yang Shun, Shang Yanhong, Xie Liang, Jia Youchao, Li Jieming, Zang Aimin, Jiang Shu.Experimental study on bi-chimeric antigen receptors modified T- lymphocytes targeting on acute myeloid leukemia[J]. Journal of International Oncology, 2018, 45(7): 385-390.
[10]	YANG Qing-Bo, LIU Fan, YU Jian-Bo.Relationship between follicular helper T cells and lymphoma[J]. Journal of International Oncology, 2018, 45(5): 312-314.
[11]	Yang Aiwu, Lin Zhimin, Zhang Jiangling, Liang Renpei, Zheng Weibin.Effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy[J]. Journal of International Oncology, 2018, 45(3): 161-165.
[12]	Xu Xiang, He Qingwen, Xiao Caiwen.Prognostic evaluation of Ki67 and derived neutrophil-lymphocyte ratio in patients with nasopharyngeal carcinoma[J]. Journal of International Oncology, 2018, 45(12): 711-715.
[13]	潘宇凯.Valuation of neutrophil to lymphocyte ratio in peripheral blood as a prognostic factor for patients with triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 824-827.
[14]	SHEN Na, LI Qing, CHENG Fan-Jun.Changes of bone marrow microenvironment of myelodysplastic syndromes[J]. Journal of International Oncology, 2016, 43(8): 715-717.
[15]	ZHOU Shao-Chun, ZHOU Wei, LI Dan, YANG Jie.Effect of dexmedetomidine on perioperative stress reaction and cellular immunity of patients with breast cancer radical surgery[J]. Journal of International Oncology, 2016, 43(7): 486-489.